TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation

Georg Nickenig and Christopher Allen discuss transcatheter replacement for the tricuspid valve and a dedicated transfemoral device in this interview, focusing on the TARGET study.

TARGET set out to answer two questions: can tricuspid regurgitation (TR) be reduced to mild or zero, and what are the safety outcomes (bleeding, myocardial infarction, stroke, pacemaker implantation and mortality)?

The trial included patients with severe to torrential TR who remained symptomatic from heart failure. Early results are encouraging: despite a population with many massive or torrential cases, more than 90% of patients had mild or less TR at one year, signalling strong efficacy for the device while safety outcomes continue to be monitored.

Watch the full interview and learn how these findings could shape the future management of tricuspid regurgitation.

This interview was filmed at PCR London Valves 2025: see more videos here.